Stockreport

Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

Instil Bio, Inc.  (TIL) 
NASDAQ:AMEX Investor Relations: nasdaq.com/symbol/til
PDF ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class m [Read more]